DGM
ALLO icon

Darwin Global Management’s Allogene Therapeutics ALLO Stock Holding History

Darwin Global Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,479,791
Closed -$12.4M – 6
2025
Q2 		$12.4M Buy
10,479,791
+30,000
+0.3% +$39.9K 0.52% 5
2025
Q1 		$16.2M Buy
+10,449,791
New +$19.7M 1.11% 3

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Darwin Global Management's ALLO Position: Q3 2025 in Review

Darwin Global Management sold out of Allogene Therapeutics (ALLO) in Q3 2025, closing a stake of 10,479,791 shares — an estimated $12.4M sold.

Darwin Global Management first reported a position in ALLO in Q1 2025 and held it in 2 quarters. The position peaked at $16.2M in Q1 2025. 170 funds tracked by Wall St. Rank hold ALLO as of Q3 2025.

  • Darwin Global Management reported no remaining Allogene Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Darwin Global Management sold 10,479,791 Allogene Therapeutics shares in Q3 2025, an estimated $12.4M.
  • Darwin Global Management first reported a position in Allogene Therapeutics in Q1 2025 and held it in 2 quarters.
  • Darwin Global Management's Allogene Therapeutics position peaked at $16.2M in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2025.

Based on Darwin Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.